PET may be used with a number of different radiotracers, but the only FDA-approved tracer for breast imaging is FDG, which received initial FDA approval in 1994 for the identification of regions associated with epileptic seizures.
Erlotinib (TarcevaR; Roche, Genentech, OSI Pharmaceuticals) has FDA/EMEA approval as single-agent treatment for patients with locally advanced or metastatic NSCLC, and FDA approval in combination with gemcitabine for first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Being implicated in the development of a number of the most lethal cancers worldwide, EGFR has long been considered as a focal target for cancer therapies, ever since the FDA approval of "Gefitinib" in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor "Osimertinib" in 2015.
Pending review by the Food and Drug Administration FDAandand the outcome of confirmatory phase III studies, PARP inhibitors could become the first FDA-approved biologic agent for ovarian cancer and also the first new FDA-approval in ovarian cancer since carboplatin and gemcitabine were approved for platinum sensitive ovarian cancer in 2006.
Panitumumab gained FDA-approval in 2006 for the treatment of patients with EGFR expressing metastatic colorectal carcinoma with disease progression while on or following fluoropyrimidine-, oralirinotecan-containingan-chemotherapyhemotheregimensimens [22].
Having received FDA-approval in 2006 for the treatment of cutaneous T cell lymphoma there is now considerable clinical experience with the use of this drug.
A recent assessment of progress in the field, from U.C.L.A., concluded, "FDA approval of new antibacterial agents decreased by 56percentnt over the past 20 years (1998-2002 vs. 1983-1987)," nothat that, in the researchers' projection of future development only six of the five hundred and six drugs currently being developed were new antibacterial agents.
Ocrelizumab has recently been granted FDA approval for both RRMS and PPMS, and represents the first FDA-approved treatment for PPMS.
Thus far, only synthetic THC, in the form of Marinol and Cesamet, has obtained FDA approval, although a mouth spray called Sativex, containing THC and CBD, is in Phase III FDA trials.
When efficacy is shown, the company that owns the drug could apply for FDA-approval or the consortium could potentially sponsor the FDA approval on its own.
In that preamble, the FDA declared that the FDCA establishes "both a 'floor' and a 'ceiling,' " so that "FDA approval of labeling … preempts conflicting or contrary State law". Id., at 3934 3935.
